B. Riley initiated coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Get Rating) in a research note released on Wednesday morning, The Fly reports. The firm issued a buy rating and a $6.00 price objective on the stock. B. Riley also issued estimates for Trevi Therapeutics’ Q1 2023 earnings at ($0.06) EPS, Q2 2023 earnings […]